Categories AlphaGraphs, Earnings, Health Care

Infographic: Anthem (ANTM) Q1 2020 Earnings Results

Anthem Inc. (NYSE: ANTM) reported a 2% decline in earnings for the first quarter of 2020 due to an increase in income tax expenses as well as higher costs and expenses. The top-line jumped by 21% driven by pharmacy product revenue related to the launch of IngenioRx as well as higher premium revenue.

Anthem (ANTM) Q1 2020 earnings review

For full-year 2020, the company expects GAAP EPS to be greater than $21 and adjusted EPS to be greater than $22.30. The company is withdrawing all other guidance metrics for 2020 until visibility improves from the unprecedented uncertainty around the COVID-19 pandemic. In response to the COVID-19 pandemic, the company has temporarily suspended share repurchase activity to enhance liquidity and financial flexibility.

Past Performance

ANTM Q4 2019 Earnings Infographic

Anthem Q3 2019 Earnings Results

Most Popular

Biogen (BIIB) stock research summary | Q3 2021

Neurological and neurodegenerative diseases affect a vast segment of the population worldwide and there is a significant demand for treatments for these conditions. Biogen (BIIB) has a strong portfolio of

Teva Pharmaceutical (TEVA) bets on market reopening to regain momentum

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA), a market leader in generic drugs, reported lower revenues for the third quarter of 2021, citing a slowdown in North American sales. Meanwhile, earnings

Goldman Sachs (GS) stock research summary | Q3 2021

Goldman Sachs (GS) exceeded analysts’ expectations, as investment banking revenue surged nearly 90%. Goldman market research report covers key aspects about the firm including company profile, financial highlights and key

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top